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Abstract. Diet is an important lifestyle factor implicated in the etiology of Alzheimer’s disease (AD), but so far it is not fully
elucidated to which nutrients the suggested protective effect of diet can be attributed. Recent evidence obtained in the amyloid-
1-42 (A42) infusion model in rats has shown that a multi-nutrient intervention known as Fortasyn™ Connect (FC) may protect
the central cholinergic system against A42-induced toxicity. FC comprises the nutritional precursors and cofactors for membrane
synthesis, viz. docosahexaenoic acid (DHA), eicosapentaenoic acid, uridine-mono-phosphate (UMP), choline, phospholipids,
folic acid, vitamins B6, B12, C, E, and selenium. In order to investigate whether the combined administration of these nutrients
may also affect AD-like pathology, we now evaluated the effects of the FC diet intervention in the transgenic APPswe/PS1dE9
mouse model with endogenous A production. In addition we evaluated the effects of diets containing the individual nutrients
DHA and UMP and their combination in this model. Between the age of 3 and 6 months, FC diet decreased brain A levels and
amyloid plaque burden in the hippocampus of APP/PS1 mice. The FC diet also reduced ongoing disintegrative degeneration
in the neocortex, as indicated by Amino Cupric Silver staining. Although all three DHA-containing diets were equally effective
in changing brain fatty acid profiles, diets differentially affected amyloid-related measures, indicating that effects of DHA
may depend on its dietary context. The current data, showing that dietary enrichment with FC reduces AD-like pathology in
APP/PS1 mice, confirm and extend our previous findings in the A42 infusion model and favor the combined administration
of relevant nutrients.
Keywords: APP/PS1 transgenic mice, Alzheimer’s disease, amyloid-, degenerative staining, DHA, Fortasyn Connect,
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INTRODUCTION
Diet is an important lifestyle factor implicated in
the etiology of dementias including Alzheimer’s dis-
ease (AD). Specific dietary patterns are associated
with lower risks of developing dementias [1–5], and
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adherence to complex dietary compositions has been
associated with better mental and physical health
[6] and reduced risk of developing AD [7, 8]. The
potentially protective effects of diet, however, cannot
easily be attributed to the actions of individual nutri-
ents, as a variety of systematic reviews conclude that
single-nutrient interventions are predominantly non-
successful [9–12]. Presumably, the combined intake
of such nutritional components is required in order to
reach efficacy.
A striking example of the added value that the simul-
taneous enrichment of nutrients can have comes from
a series of experiments showing that the combina-
tion of the phospholipid precursors docosahexaenoic
acid (DHA) and uridine-mono-phosphate (UMP) can
act synergistically in stimulating membrane phos-
pholipid synthesis, increasing dendritic spine density,
and improving learning and memory [13–15]. The
nutrients work by increasing the substrate-saturation
of low-affinity enzymes that synthesize the phos-
pholipids [16]. All these observations were made in
healthy rodents, but the effects reported are consid-
ered to be very relevant for AD, in which brain
phospholipids are reduced [17, 18] and which is char-
acterized by a loss of synaptic connections [19, 20]
thought to underlie the loss of cognitive functioning.
In line with this suggestion, we recently reported that
a multi-nutrient composition called Fortasyn™ Con-
nect (FC) protected the central cholinergic system
against amyloid- 1-42 (A42)-induced toxicity in a
membrane toxicity model of AD, the A42 infused
rat [21]. Based on this, we were interested to see
whether combined administration of nutrients that
affect membrane synthesis and composition may also
affect endogenous membrane-bound processes rele-
vant to AD, such as A production and amyloid plaque
formation.
The aim of the present study was to investigate the
effects of nutritional interventions on the development
of AD-like pathological changes in female transgenic
APP/PS1 mice. These female mice show A plaque
formation as early as 4–5 months of age [22, 23],
which is sensitive to dietary manipulations [24]. We
carried out two experiments in which dietary interven-
tions were started at the age of 3 months and continued
for another 3 months. In both experiments, effects of
diets were assessed on brain composition and pathol-
ogy, using A ELISA, fatty acid analysis, as well as
immunohistochemical techniques to assess amyloid
plaque burden (A42 stain) and ongoing degener-
ative burden (deOlmos Amino Cupric Silver stain
[25, 26]).
In a first experiment we evaluated the effects of the
multi-nutrient FC composition that was designed to
stimulate synaptic membrane formation, comprising a
full set of precursors and cofactors for membrane syn-
thesis, including UMP, DHA, eicosapentaenoic acid
(EPA), choline, vitamin B6, vitamin B12, folic acid,
phospholipids, vitamin C, vitamin E, and selenium.
From these nutrients, UMP, DHA, and choline are
all precursors for the Kennedy cycle for phospho-
lipid synthesis [16, 27]. Dietary EPA contributes as
a precursor to raise brain levels of DHA [28, 29].
The phospholipids act both as precursors and cofac-
tors, by providing choline and diacylglycerol (DAG)
for the Kennedy cycle and by enhancing the avail-
ability of DHA, respectively. The remaining cofactors,
i.e., the B-vitamins and the antioxidants, are neces-
sary to enable and support the biochemical processes
involved in phospholipid synthesis and/or to increase
the availability of the membrane precursors, either by
stimulating the endogenous synthesis or by reducing
their degradation (e.g., [30, 31]). In addition, sele-
nium may enhance PC synthesis by increasing the
activity of a key enzyme in the Kennedy cycle, CDP-
choline:DAG cholinephosphotransferase [32]. Levels
of choline, phospholipids, and polyunsaturated fatty
acids like DHA are known to be decreased in the brains
of AD patients [17, 18, 33], and epidemiological stud-
ies have reported that AD patients also have lower
plasma levels of DHA, folic acid, vitamin B12, vitamin
E, and vitamin C as compared to age-matched controls
[34–36]. The effects of the FC diet intervention were
studied both in APP/PS1 mice and their wild type
littermates.
In a second experiment we evaluated the effects of
diets that were supplemented with either DHA or UMP
or the combination of these two nutrients in transgenic
mice. DHA may reduce A release by directing amy-
loidogenic processing of A protein precursor (APP)
toward non-amyloidogenic processing [37]. DHA has
been evaluated before in various transgenic mouse
models of AD pathology [24, 38, 39], but has not
always been found to affect amyloid production or
plaques [40, 41]. It has been suggested that the effi-
cacy of DHA in reducing amyloid plaque formation
may depend on its dietary context [42]. UMP has not
been evaluated before in transgenic mouse models of
AD, but has repeatedly been shown to act synergis-
tically in combination with DHA on structural brain
changes in healthy rodents [15, 16]. We now tested the
combination of DHA and UMP to see whether these
nutrients would also show synergistic effects on brain
parameters in APP/PS1 mice.
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MATERIALS AND METHODS
Animals and dietary interventions
The APPswe/PS1dE9 founders were obtained from
Johns Hopkins University, Baltimore, MD, USA
(Borchelt and Jankowsky, Department of Pathology)
and a colony was established at the Radboud Uni-
versity Nijmegen Medical Centre, The Netherlands.
The mice had been created by co-injection of chimeric
mouse/human APPswe (mouse APP695 harbor-
ing a human A domain and mutations K595N and
M596L linked to Swedish familial AD pedigrees) and
human PS1-dE9 (deletion of exon 9) vectors con-
trolled by independent mouse prion protein promoter
elements. This line (line 85 [22]) was originally main-
tained in a hybrid background by backcrossing to
C3HeJ × C57Bl6/J F1 mice. For the present work,
the breeder mice were backcrossed to C57Bl6/J for 9
generations.
Female APP/PS1 transgenic mice and wild type
littermate controls were housed in groups of 4–6
animals per cage. The animals were kept in a con-
trolled environment, with temperature at 20–22◦C,
humidity at 50–60%, and lights on between 07:00
and 19:00 h. Food and water were freely available
throughout the study. Some animals died for unknown
reasons during the study, and were discarded from the
experiment.
At the age of 3 months, the mice were subjected
to the experimental diets for a period of 3 months, as
indicated in Table 1. In experiment A, both wild type
and transgenic mice were fed with either a Control
diet or a FC diet. In experiment B, groups of trans-
genic mice were fed DHA, UMP, or DHA + UMP diets.
Experiment B was conducted to test the individual and
combined effects of DHA and UMP supplementation.
The diets differed in composition with regard to the
fat blends used, as well as a number of supplemented
nutrients as indicated in Tables 2 and 3. The source
of DHA was fish oil (tuna, Numega, and EPA-28SP;
Lithos Foods). All diets were isoenergetic, were based
on the Control diet, fulfilled all dietary requirements,
and were manufactured and pelleted by Research Diet
Services (Wijk bij Duurstede, The Netherlands). All
diets were stored at −20◦C until use, in order to pre-
vent oxidation of lipids. Reanalysis of the diets at the
end of the study confirmed that all fatty acids were still
present in the original amounts.
All animal experimental protocols were conducted
in accordance with European and Dutch laws and
institutional guidelines and approved by the local
Table 1
Overview of groups of mice and the experimental diets for experi-
ments A and B
Experiment Genotype Diet # mice




B Transgenic Control 7
DHA 5
UMP 8
DHA + UMP 7
ethics committee (DEC Consult, Bilthoven, The
Netherlands).
Tissue preparation
At the age of 6 months, mice were perfused transcar-
dially with ice-cold saline containing 5.8 mM EDTA
under deep sodium pentobarbital anesthesia. Brains
were rapidly removed and divided at the midline. The
left hemisphere was snap frozen in liquid nitrogen and
stored at −80◦C until freeze drying (Virtis Advantage
EL, Depex) for A ELISA and fatty acid analysis.
Freeze dried hemispheres were grinded in a mixer mill
(Retsch, MM200) for 45 s at 20 Hz and the tissue was
stored at −20◦C until further analysis. The right hemi-
sphere was fixed in 4% paraformaldehyde for 24 h and
then rinsed in PBS and stored in PBS with 0.1% azide
until further processing for histological analyses.
Aβ ELISA
For the human A ELISA assay on brain sam-
ples of transgenic mice, 20 mg of grinded freeze dried
brain tissue was homogenized in 200L PBS (Invitro-
gen). The homogenate was centrifuged at 13,000 rpm,
10 min at 4◦C. The supernatant was removed. The pel-
let was resuspended in 80L 4× formic acid (VWR
International) and sonicated for 10 min. The sample
was neutralized by adding 720L 4 M Tris. After cen-
trifuging (13.000 rpm, 10 min at 4◦C), the supernatant
was used to detect A, using the hAmyloid 42 Brain
ELISA and the hAmyloid 40 Brain ELISA (Genetics
Company, TKbrain-Set). According to the manufac-
turer’s protocol, a standard curve was made with a
range of 25–500 pg/ml. The samples were diluted
50–100×using the dilution buffer supplied by the man-
ufacturer. 50L of antibody conjugate solution was
added to the 96 wells plate before 50L of standard or
sample was added. The plates were covered and mixed
thoroughly on a plate shaker. After an overnight incu-
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Table 2
Detailed compositions of the experimental diets that were used in experiments A and B. All diets were isoenergetic, contained 5% fat (oli
blend specified in Table 3), and also contained standard vitamin and mineral premix, providing recommended daily amounts of these nutrients.
Specific nutrients or combinations of nutrients that were supplemented on top of the standard Control diet are indicated in the lower part of the
table (UMP through Vit.B12). All amounts of nutrients are indicated in g/100 g of diet. All diets were presented to the animals as pellets
Ingredients (g/100 g diet) Experiment A Experiment B
Control FC Control DHA UMP DHA + UMP
Wheat 25.87 23.82 25.87 25.87 24.87 24.87
Barley 25.00 25.00 25.00 25.00 25.00 25.00
Semolina 25.00 25.00 25.00 25.00 25.00 25.00
Soybean meal 8.50 8.50 8.50 8.50 8.50 8.50
Whey 5.00 5.00 5.00 5.00 5.00 5.00
Bentonite 1.00 1.00 1.00 1.00 1.00 1.00
Vitamin/mineral premix 2.20 2.20 2.20 2.20 2.20 2.20
CaCO3 1.40 1.40 1.40 1.40 1.40 1.40
Dicalciumphosphate 0.30 0.30 0.30 0.30 0.30 0.30
NaCl 0.50 0.50 0.50 0.50 0.50 0.50
L-lysine HCl 0.18 0.18 0.18 0.18 0.18 0.18
DL-methionine 0.05 0.05 0.05 0.05 0.05 0.05
Oil blend 5.00 5.00 5.00 5.00 5.00 5.00
Providing DHA – 0.757 – 0.757 – 0.757
Providing EPA – 0.189 – 0.189 – 0.189
UMP – 1.000 – – 1.000 1.000
Choline – 0.313 – – – –
Lecithin – 0.412 – – – –
Vitamin E – 0.157 – – – –
Vitamin C – 0.160 – – – –
Selenium – 0.000111 – – – –
Folic acid – 0.0007 – – – –
Vitamin B6 – 0.0027 – – – –
Vitamin B12 – 0.0000011 – – – –
Table 3
Specification of the oil blends that were used for the various diets in experiments A and B. All diets contained 5% of fat. Relative amounts of
saturated fatty acids (SFA), mono-unsaturated fatty acids (MUFA), and poly-unsaturated fatty acids (PUFA) were similar for all diets
Experiment A Experiment B
Control FC Control DHA UMP DHA UMP
Source Soy oil 1.39 1.39 1.39
Coconut oil 0.65 0.10 0.65 0.10 0.65 0.10
Corn oil 2.96 1.75 2.96 1.75 2.96 1.75
Fish oil 3.15 3.15 3.15
%FA SFA 24 26 24 26 24 26
MUFA 24 24 24 24 24 24
PUFA 52 49 52 49 52 49
bation at 4◦C, the plates were washed 5 times with
the supplied washing buffer. 100L of enzyme conju-
gate was added to wells for 30 min incubation at room
temperature. The plate was washed 5 times and subse-
quently 100L of substrate was added. After 25 min
incubation in the dark at room temperature, 50L of
stop solution was added and the plates were measured
at 450 nm with a reference filter of 620–650 nm.
Histology
The fixed hemispheres were processed by Neu-
roScience Associates (Knoxville, USA), who
subsequently stained two adjacent series of sections.
One series of sections was subjected to an immuno-
histochemical staining with an antibody for A1-42
to reveal amyloid plaques. Another series of sections
was stained with the deOlmos Amino Cupric Silver
method to reveal ongoing disintegrative degeneration
[25, 26]. In short, hemispheres, arranged in 4 × 8
arrays, were embedded in a gelatin matrix using
MultiBrain® Technology. Each block of embedded
hemispheres was rapidly frozen by immersion in
isopentane chilled to −70◦C with crushed dry ice.
Frozen sections (35m) were then cut in the coronal
plane throughout the striatum-hippocampus part of the
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hemispheres. Sections to be stained with the A anti-
body were stored in antigen preserve storage buffer;
the sections to be stained with the Amino Cupric
Silver method were stored in Fix-storage buffer.
Image analysis
Images of the stained sections were obtained by
using. Slide (Olympus, Zoeterwoude, The Nether-
lands) and image analyses were performed with
AnalySIS Five (Olympus). Using the unbiased sam-
pling method, regions of interest (ROI) were selected
in the scanned sections for both the hippocampus and
the overlying neocortex. Surface areas were stereo-
logically quantified using the Cavalieri method. Total
area stained per ROI was determined by densitomet-
ric measurements and expressed as plaque burden
(A1-42 staining) or degenerative burden (visualized
with deOlmos Amino Cupric Silver stain for disinte-
grative degeneration), calculated as the ratio of stained
surface and total ROI surface for each respective brain
area (hippocampus or neocortex).
Brain fatty acid analysis
Fatty acid analyses were performed on 20 mg of the
grinded freeze dried brain tissue that was homoge-
nized in 1% EDTA solution. Total lipid content was
extracted from the homogenates by adding methanol
and dichloromethane. Subsequently, samples were
centrifuged at 3000 rpm for 10 min and the lower layer
(dichloromethane and lipids) was collected. 200l of
the dichloromethane layer was evaporated to dryness in
a SpeedVac® concentrator. 2 mL methanol and 40L
concentrated sulfuric acid were added to the dried
extract. The samples were heated at 100◦C for 60 min,
and 2 mL hexane and 0.5 mL 2.5 M sodium hydroxide
solution were added. After vortexing and centrifug-
ing the samples for 5 min at 3000 rpm, the upper
layer was collected and evaporated in a SpeedVac®.
The fatty acids were dissolved in 125L iso-octane
and analyzed on a GC-FID with a CP-SIL88 column
(50 m × 0.25 mm id. 0.22m film thickness).
Statistics
All statistical analyses were performed using SPSS
15.0 (SPSS Benelux). Effects of the different diets on
body weight were analyzed using repeated measures
ANOVA with Weeks having 13 levels as within-subject
variable. Between-subject variables in experiment A
consisted of Genotype (transgenic and wild type)
and/or Diet (Control and FC). In experiment B, the
between-subject variable Diet had 4 levels (Control,
DHA, UMP, and DHA + UMP). Effects of diets on A
ELISA, amyloid plaque burden, and degenerative bur-
den were analyzed using univariate ANOVA. Effects
of diets on brain fatty acid profiles were analyzed using
multivariate ANOVA. For all analyses, differences
were considered significant at p < 0.05. Post hoc com-
parisons were performed when appropriate. Next to the
primary statistical analyses according to the original
experimental design, a posteriori exploratory statisti-
cal analyses were performed using ANOVA to compare
effects of FC diet (experiment A) and DHA + UMP diet
(experiment B) on A pathology in transgenic mice.
RESULTS
Body weights
In both experiment A and B, body weights
increased over Weeks (F(12,372) = 79.95; p < 0.001
and F(12,276) = 94.63; p < 0.001, respectively). No
main effect of Genotype, Diet, or their interaction
was found to be significant. A significant Genotype x
Weeks interaction in experiment A (F(12,372) = 3.45;
p < 0.001) indicated that weight gain over time was
larger in wild type mice, irrespective of Diet.
Amyloid and related pathological changes:
experiment A
Data obtained in experiment A with respect to brain
amyloid parameters are displayed in Fig. 1.
Aβ ELISA
In brain homogenates of transgenic mice, the
FC diet significantly reduced both the levels of
A42 (F(1,12) = 6.28; p < 0.05; Fig. 1a) and A40
(F(1,12) = 5.81; p < 0.05; Fig. 1b) as compared to Con-
trol diet.
Amyloid plaque burden
APP/PS1 transgenic mice had a higher amyloid
plaque burden in the hippocampus than wild type
mice (F(1,31) = 334.4; p < 0.001; Fig. 1c). The FC diet
reduced the amyloid plaque burden in the hippocam-
pus compared to the Control diet (F(1,31) = 6.28;
p < 0.02). A significant Diet x Genotype interaction
(F(1,31) = 6.22; p < 0.02) was found.Post-hoc analyses
showed no significant effect of Diet in wild type mice
(p = 0.68). Similar to the hippocampus, the amyloid
plaque burden in the neocortex of transgenic mice was
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Fig. 1. Effects of Control and FC diets on brain amyloid related parameters in APP/PS1 transgenics and their wild type mice in experiment
A. All graphs display means (+SEM). Graphs on the left display levels of A42 (a) and A40 (b) as measured by ELISA in freeze dried
brain homogenates from transgenic mice. Graphs in the middle display percentage amyloid plaque burden as indicated by A42 staining in
the hippocampus (HPC, c) and the neocortex (CTX, d) of wild type and transgenic mice. Graphs on the right display percentage degenerative
burden as indicated by Amino Cupric Silver staining in the hippocampus (HPC, e) and the neocortex (CTX, f) of wild type and transgenic mice.
Dietary interventions are indicated at the x-axes. *p < 0.05 versus Control.
elevated in comparison to wild types (F(1,31) = 204.4;
p < 0.001; Fig.1d). The FC diet did not affect amyloid
plaque burden in the neocortex (p = 0.48).
Degenerative burden
Although some ongoing degeneration was present
in the brains of all mice, the degenerative burden in
transgenic mice was significantly increased in both
the hippocampus (F(1,31) = 97.3; p < 0.001; Fig. 1e)
and the neocortex (F1, 31) = 169.4; p < 0.001; Fig. 1f)
as compared to wild type mice. The FC diet did
not affect degenerative burden in the hippocampus
(F(1,31) = 1.75; p = 0.195). In the neocortex, however,
the FC diet induced a significant decrease in degener-
ative burden (F(1,31) = 4.44; p < 0.05), irrespective of
Genotype.
Representative illustrations of plaque burden (A)
and degenerative burden (Amino CuAg) in the brains
of animals from experiment A are given in Fig. 2.
Amyloid and related pathological changes:
experiment B
Data obtained in experiment B with respect to brain
amyloid parameters are displayed in Fig. 3.
Aβ ELISA
The dietary interventions affected brain levels of
A42 (F(3,23) = 3.67; p < 0.05; Fig. 3a) and A40
(F(3,23) = 3.63; p < 0.05; Fig. 3b). Levels of A42 in
the DHA + UMP group were higher than those in the
DHA and UMP groups (both p < 0.05). Levels of A40
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Fig. 2. Representative images of A42 (A; top row) and deOlmos Amino Cupric Silver (Amino CuAg; bottom row) staining in brain sections
from APP/PS1 mice of experiment A. Images on the left show amyloid plaques and associated degenerative staining in adjacent sections in
a mouse on the Control diet. Images on the right are taken from adjacent sections in a mouse on the FC diet. Group means of plaque burden
and degenerative burden in hippocampus and neocortex are shown in Fig. 1c–f. The FC diet reduced plaque burden in the hippocampus and
degenerative burden in the neocortex.
were reduced by the UMP diet as compared to both the
Control and the DHA + UMP diets (both p < 0.05).
Amyloid plaque burden
Dietary interventions with DHA, UMP, or
DHA + UMP in APP/PS1 transgenic mice did not
induce significant changes in amyloid plaque burden
as compared to the Control diet in either the hippocam-
pus (F(3,23) = 1.16; p = 0.35; Fig. 3c) or the neocortex
(F(3,23) = 1.36; p = 0.28; Fig. 3d). Representative
illustrations of plaque burden in the brains of animals
from experiment B are given in Fig. 4.
Degenerative burden
Degenerative burden in the hippocampus was
not significantly affected by dietary interventions
with DHA, UMP, or DHA + UMP in APP/PS1
transgenic mice (F(3,23) = 2.09; p = 0.129; Fig. 3e).
Similarly, the latter diets did not affect degenerative
burden in the neocortex (F(3,23) = 0.80; p = 0.506;
Fig. 3f).
A posteriori exploratory comparisons:
experiments A and B
Next to the primary statistical analyses according
to the original experimental design, it was decided to
perform some a posteriori exploratory statistical anal-
yses. For the measures related to A pathology in
transgenic mice, the effects of the FC diet in exper-
iment A were directly compared to the effects of
the DHA + UMP diet in experiment B. These com-
parisons were considered relevant in the light of the
original aim concerning potential synergistic actions
of nutrients. The results of the analyses indicated that,
compared to the DHA + UMP diet, the FC diet resulted
in significantly lower levels of A42 (F(1,12) = 11.20;
p < 0.01) and A40 (F(1,12) = 50.19; p < 0.001), and
a lower amyloid plaque burden in the hippocam-
pus (F(1,12) = 5.02; p < 0.05) but not in the neocortex
(p = 0.36). As compared to the DHA + UMP diet, the
FC diet resulted in significantly lower degenerative
burden in the hippocampus (F(1,12) = 6.33; p < 0.05)
184 L.M. Broersen et al. / Multi-Nutrient Approach Reduces AD-Like Pathology
Fig. 3. Effects of Control, DHA, UMP, and DHA + UMP diets on brain amyloid related parameters in APP/PS1 transgenics mice in experiment
B. All graphs display means (+SEM). Graphs on the left display levels of A42 (a) and A40 (b) as measured by ELISA in freeze dried brain
homogenates. Graphs in the middle display percentage amyloid plaque burden as indicated by A42 staining in the hippocampus (HPC, c)
and the neocortex (CTX, d). Graphs on the right display percentage degenerative burden as indicated by Amino Cupric Silver staining in the
hippocampus (HPC, e) and the neocortex (CTX, f). Dietary interventions are indicated at the x-axes. *p < 0.05 versus Control; +p < 0.05 versus
DHA; #p < 0.05 versus UMP.
and marginally lower degenerative burden in the neo-
cortex (F(1,12) = 3.82; p = 0.07).
Brain fatty acids
The relative amounts of different fatty acids in the
lipid fraction of the brain homogenates from exper-
iment A and B are displayed in Tables 4 and 5,
respectively.
In experiment A (Table 4), small differences
between brain fatty acid profiles of APP/PS1
transgenic and wild type mice were noted. Main
effects of Genotype were found for 18:0 (stearic
acid; F(1,31) = 5.31; p < 0.05), 18 : 1n9 (oleic
acid; F(1,31) = 2.90; p < 0.05), and total PUFAs
(F(1,31) = 4.23; p < 0.05). For 22 : 6n3 (DHA) the
Diet × Genotype interaction just failed to reach
significance (F(1,31) = 3.24; p = 0.08), indicating that
the Diet-induced increase in DHA tended to be larger
in transgenic mice. The FC diet reduced n6 PUFAs
(F(1,31) = 575.86; p < 0.001) and increased n3 PUFAs
(F(1,31) = 125.42; p < 0.001) relative to the Control
diet in both APP/PS1 transgenic and wild type mice.
The FC diet decreased the relative amount of 20 : 4n6
(AA; F(1, 31) = 626.12; p < 0.001) and increased DHA
(F(1,31) = 694.37; p < 0.001). The FC diet decreased
the total relative amount of PUFAs (F(1,31) = 8.00;
p < 0.01). The total relative amount of MUFAs was
increased by the FC diet (F(1,31) = 16.30; p < 0.001),
mainly due to an increase in 18 : 1n9 (F(1,31) = 88.39;
p < 0.001).
In experiment B (Table 5), the DHA diet and
the DHA + UMP diet similarly affected brain fatty
acid profiles as compared to both the Control
diet and the UMP diet. Both DHA-containing
diets decreased 18:0 (F(3,23) = 3.14; p < 0.05), and
increased both 18:1n9 (F(3,23) = 18.27; p < 0.001) and
the total relative amount of MUFAs (F(3,23) = 3.49;
p < 0.05). The DHA-containing diets decreased the
n6 PUFAs (F(3,23) = 178.01; p < 0.001) including AA
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Fig. 4. Representative images of A42 (A) staining in brain sections from APP/PS1 mice of experiment B. From left to right, images from
mice on the Control diet, the DHA only diet, the UMP only diet, and the DHA + UMP diet are presented. Group means of plaque burden in
hippocampus and neocortex, as shown in Fig. 3c, d, were not significantly different for the Diet groups.
Table 4
Relative amounts of the major individual fatty acids and their classes in the lipid fraction of the brain homogenates from experiment A. Data are
expressed as means, with SEMs within parentheses. Statistically significant main effects (p < 0.05) of Genotype (G) and Diets (D) are indicated
at the right hand side; trends (p < 0.10) are indicated within parentheses
Expt. A Wild type Transgenic Main
Control FC Control FC effects
16 : 0 20.37 (0.11) 20.50 (0.16) 20.19 (0.13) 20.47 (0.12)
18 : 0 16.69 (0.07) 16.45 (0.14) 16.95 (0.17) 16.77 (0.12) G
18 : 1n9 15.27 (0.08) 16.26 (0.12) 15.08 (0.12) 16.02 (0.08) D,G
20 : 4n6 8.35 (0.08) 6.32 (0.08) 8.34 (0.06) 6.47 (0.05) D
22 : 6n3 12.43 (0.14) 13.85 (0.18) 12.43 (0.13) 14.44 (0.17) D,(D × G)
SFA 39.26 (0.12) 39.06 (0.30) 39.38 (0.28) 39.19 (0.20)
MUFA 24.01 (0.22) 25.07 (0.22) 23.82 (0.21) 24.53 (0.17) D
PUFA 25.71 (0.23) 24.82 (0.21) 25.92 (0.22) 25.53 (0.18) D,G
n6 12.73 (0.12) 9.84 (0.10) 12.95 (0.15) 9.94 (0.11) D
n3 12.98 (0.18) 14.98 (0.22) 12.97 (0.19) 15.60 (0.19) D
(F(3,23) = 139.00; p < 0.001), while they increased the
n3 PUFAs (F(3,23) = 68.29; p < 0.001) including DHA
(F(3,23) = 58.93; p < 0.001).
DISCUSSION
The present results indicate not only that dietary
intervention can affect AD-like pathology in transgenic
APP/PS1 mice, but also that dietary composition,
i.e., the simultaneous presence of specific nutrients,
is an important factor in determining their efficacy.
The specific multi-nutrient enriched FC diet was shown
to reduce several pathology-related measures, includ-
ing total brain A42 and A40 levels as measured
by ELISA. In addition, by applying immunohisto-
chemical techniques and a stereological approach to
determine brain plaque burden, it was shown that
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Table 5
Relative amounts of the major individual fatty acids and their classes in the lipid fraction of the brain homogenates from experiment B. Data
are expressed as means, with SEMs within parentheses. Statistically significant main effects of Diets (D) are indicated at the right hand side.
Post-hoc comparisons indicated that both DHA-containing diets (DHA and DHA + UMP) differed from the remaining diets (Control and UMP)
Expt. B Transgenic Main
Control DHA UMP DHA UMP effects
16 : 0 20.19 (0.13) 20.45 (0.21) 20.69 (0.26) 20.38 (0.21)
18 : 0 16.95 (0.17) 16.64 (0.11) 17.20 (0.19) 16.62 (0.10) D
18 : 1n9 15.08 (0.12) 16.00 (0.21) 14.96 (0.07) 15.97 (0.14) D
20 : 4n6 8.34 (0.06) 6.50 (0.13) 8.38 (0.07) 6.45 (0.11) D
22 : 6n3 12.43 (0.13) 14.40 (0.22) 12.48 (0.12) 14.59 (0.17) D
SFA 39.38 (0.28) 39.11 (0.28) 39.97 (0.40) 39.04 (0.27)
MUFA 23.82 (0.21) 24.48 (0.42) 23.55 (0.15) 24.55 (0.32) D
PUFA 25.92 (0.22) 25.57 (0.26) 25.99 (0.14) 25.56 (0.23)
n6 12.95 (0.15) 9.99 (0.18) 12.93 (0.09) 9.88 (0.12) D
n3 12.97 (0.19) 15.58 (0.23) 13.06 (0.12) 15.67 (0.20) D
this multi-nutrient enrichment affected both amyloid
plaque burden and degenerative burden in different
brain structures. FC-induced reductions reached sta-
tistical significance for amyloid plaque burden in the
hippocampus and for degenerative burden in the sur-
rounding neocortex. These findings are in line with
and extend our recent findings obtained in the A
infusion model [21], by showing that FC diet may
not only affect the A-induced membrane toxicity
and neurodegeneration, but also the membrane-bound
production of A. In contrast, diets that were only
enriched in DHA, UMP, or their combination yielded
non-significant changes in amyloid plaque burden and
degenerative burden in hippocampus and neocortex in
these mice, although the UMP diet did reduce brain
A40 levels. It should be noted that the DHA diet and
the DHA + UMP diet were equally effective in rais-
ing brain DHA levels as the FC diet. Together these
data indicate that the multi-nutrient enrichment by FC
is effective in reducing pathological changes in the
APP/PS1 model, and that the effects of this dietary
intervention are not easily attributed to one or more of
its individual components.
Since especially some animals on the DHA diet
died over the course of the study, this group was left
with a relative small number of subjects. It is possible
that this may have hampered us to observe statistically
significant effects of the diet on AD-like pathology
compared to Controls. Nevertheless, in experiment
B the largest differences were found between the
DHA + UMP diet and the DHA or UMP only diets,
underlining the importance of dietary context. This
importance of dietary context was further supported
by the results of the a posteriori exploratory analyses
showing that the FC diet was more effective in
reducing A pathology than the combination of
nutrients in the DHA + UMP diet.
Previously, various studies have examined the
effects of single-nutrient dietary supplementation on
brain amyloid in different transgenic mouse models of
AD. A number of these studies focused on the effects
of supplementation of DHA or DHA-containing fish
oil, with variable outcome. In an early study, Lim and
coworkers [43] reported that a high DHA diet sig-
nificantly decreased amyloid burden in aged Tg2576
mice, but only as compared to a DHA-depleting
diet. In 3xTg-AD mice, dietary supplementation of
DHA reduced soluble, but not insoluble A levels
using whole-brain homogenates [39]. However, a more
recent study found no significant effects of DHA con-
sumption on A pathologies in frontal cortex samples
of 3xTg-AD mice [41]. Similarly, the present findings
obtained with DHA in experiment B are not at variance
with previous observations in the APP/PS1 model. In
this model, some reductions of hippocampal A lev-
els and/or hippocampal plaque load induced by fish
oil containing diets have been reported [24], albeit not
consistently [40]. In a series of experiments using long
term dietary interventions in the APP/PS1 model, it
was shown that fish oil may reduce vascular A in the
neocortex more readily than parenchymal A plaques
in the hippocampus [44]. In addition, it was shown that
the effectiveness of fish oil diets on reducing neocorti-
cal A plaque load in this model may depend on both
the age at which the intervention is started and on the
length of the intervention [45]. Importantly, the present
data indicate that the effectiveness of fish oil contain-
ing diets also depends on the concomitant availability
of additional nutrients. This observation is in line with
a recent report suggesting that the influence of DHA
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on amyloid plaque formation may depend upon the
composition of the diet in which it is supplied [42].
To date, the effects of UMP administration on AD-
like pathology in mouse models have less extensively
been investigated than those of DHA. Nevertheless, the
effects of UMP in experiment B were more pronounced
than those of DHA and reached statistical significance
for brain A40 levels. The underlying mechanism by
which UMP may affect A production is unknown, but
might involve changes in APP processing. Oral intake
of UMP has been shown to increase brain levels of UTP
[46] that may activate brain P2Y receptors [47, 48]. In
vitro studies have shown that P2Y2 receptor activation
by UTP resulted in enhanced non-amyloidogenic pro-
cessing of APP [49]. Such a shift in APP processing
would be expected to result in decreased A release.
In view of the separate effects of DHA and UMP
observed in experiment B, the results obtained with
combined administration of DHA + UMP are surpris-
ing. Thus, whereas UMP reduced brain A40 levels
as compared to Control diet, the combination of
DHA + UMP induced an increase in A40 as com-
pared to UMP diet. Similarly, the combination of
DHA + UMP induced an increase in brain A42 lev-
els as compared to the DHA diet and the UMP diet,
while non-significant reductions in brain A42 levels
were observed with the single-nutrient diets. Similar
tendencies were observed for plaque burden and degen-
erative burden in the hippocampus and the neocortex.
These seemingly contrasting findings are not easily
explained. However, the difference in effect on amyloid
pathology induced by the DHA diet, the DHA + UMP
diet, and the FC diet demonstrates that the effects of
these nutritional interventions are not the mere sum
of the effects of their individual components. Inter-
estingly, all these three DHA-containing diets induced
very similar changes in brain fatty acid profiles, with
increases in DHA and oleic acid, and decreases in
AA, despite differences in effects on pathology. First,
these data show that increased brain levels of DHA
are not sufficient to decrease A production, amy-
loid plaque burden and degeneration in APP/PS1
mice. Second, these data indicate that the combined
administration of nutrients may yield seemingly unex-
pected cumulative actions. Co-administration of the
dietary precursors for phospholipid synthesis DHA,
UMP, and choline has previously been shown to
stimulate neuronal membrane synthesis and dendritic
spine formation more than enrichment of a single pre-
cursor [16]. Whether the stimulation of membrane
synthesis and spine formation may have increased
APP processing and subsequent A production in
the APP/PS1 mice remains to be determined. Third,
these data indicate that nutrients present in FC other
than DHA and UMP contribute significantly to the
overall effect of this multi-nutrient mixture on AD-like
pathology. Indeed, several studies using single nutri-
ent enrichment provide some, albeit weak, support for
the potential beneficial effects of these nutrients. For
instance, in line with the idea that antioxidants like vita-
mins E and C may improve the neuroprotective effects
of DHA [50], vitamin E was shown to help reduce
A levels and amyloid deposition in young Tg2576
mice [51], although combined administration of vita-
mins E and C did not reduce amyloid deposition in
APP/PS1 mice [52]. Similarly, B-vitamin deficiency
has sometimes been found to increase A levels and
deposition in Tg2576 mice [53], but not always [54].
The effects of combined B-vitamins on A production
may result from changes in - and -secretase activity
[55]. In this respect there is an overlap in modes of
action with those of nutrients like DHA [37], which
may help to understand the efficacy of a multi-nutrient
approach. An elegant example of the concerted action
of the nutrients in FC on membrane bound G-protein
coupled receptor functioning is provided by Savelkoul
et al. [56].
In line with previous reports [22, 23, 57], we
observed higher brain levels of A42 than A40 in
young adult APP/PS1 animals of 6 months. Using
an A42 antibody for immunohistochemistry, we also
noted at this stage an anatomical differentiation in the
development of amyloid plaques, showing higher lev-
els of amyloid plaque burden in the neocortex than in
the hippocampus. In the APP/PS1 mice, degenerative
staining displayed a similar anatomical differentiation
and a close overlap with amyloid staining, supporting
a link between A42 levels, amyloid plaque forma-
tion and neurotoxicity in these mice. In wild type
mice we also observed some degenerative staining, and
interestingly, the FC diet reduced neocortical neurode-
generation in wild type and transgenic animals to a
similar extent, suggesting that the diet may have pro-
tective effects irrespective whether the degeneration is
caused by amyloid toxicity.
The present effects obtained with the multi-nutrient
enriched FC diet confirm and extend recent observa-
tions in the A infusion model [21], showing that
the same FC diet reduced both the neuroanatomical
and behavioral consequences of A toxicity. We now
show that this multi-nutrient enrichment effectively
reduces A production and AD-like pathology in the
APP/PS1 mouse model, while enrichment with DHA,
UMP, or their combination had little effect. Whether
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the observed reductions in pathology may contribute
to the preservation of cognitive performance remains
to be determined. It may however be speculated that
the presently observed reductions in A production
and amyloid-related neurodegeneration may be part
of the mechanisms underlying observed improvements
of memory performance following this multi-nutrient
intervention in mild AD patients [58, 59]. Additional
studies investigating the effects of longer term dietary
interventions on cognitive performance in APP/PS1
mice, AD patients, and subjects with prodromal AD
are currently ongoing.
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